Literature DB >> 19805305

XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.

Robert Schlaberg1, Daniel J Choe, Kristy R Brown, Harshwardhan M Thaker, Ila R Singh.   

Abstract

Xenotropic murine leukemia virus-related virus (XMRV) was recently discovered in human prostate cancers and is the first gammaretrovirus known to infect humans. While gammaretroviruses have well-characterized oncogenic effects in animals, they have not been shown to cause human cancers. We provide experimental evidence that XMRV is indeed a gammaretrovirus with protein composition and particle ultrastructure highly similar to Moloney murine leukemia virus (MoMLV), another gammaretrovirus. We analyzed 334 consecutive prostate resection specimens, using a quantitative PCR assay and immunohistochemistry (IHC) with an anti-XMRV specific antiserum. We found XMRV DNA in 6% and XMRV protein expression in 23% of prostate cancers. XMRV proteins were expressed primarily in malignant epithelial cells, suggesting that retroviral infection may be directly linked to tumorigenesis. XMRV infection was associated with prostate cancer, especially higher-grade cancers. We found XMRV infection to be independent of a common polymorphism in the RNASEL gene, unlike results previously reported. This finding increases the population at risk for XMRV infection from only those homozygous for the RNASEL variant to all individuals. Our observations provide evidence for an association of XMRV with malignant cells and with more aggressive tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805305      PMCID: PMC2739868          DOI: 10.1073/pnas.0906922106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

Review 1.  Cancer burden in the year 2000. The global picture.

Authors:  D M Parkin; F I Bray; S S Devesa
Journal:  Eur J Cancer       Date:  2001-10       Impact factor: 9.162

2.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.

Authors:  Graham Casey; Phillippa J Neville; Sarah J Plummer; Ying Xiang; Lisa M Krumroy; Eric A Klein; William J Catalona; Nina Nupponen; John D Carpten; Jeffrey M Trent; Robert H Silverman; John S Witte
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

3.  Assays for retroviral reverse transcriptase.

Authors:  A Telesnitsky; S Blain; S P Goff
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

4.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

5.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer.

Authors:  Nicole Fischer; Olaf Hellwinkel; Claudia Schulz; Felix K H Chun; Hartwig Huland; Martin Aepfelbacher; Thorsten Schlomm
Journal:  J Clin Virol       Date:  2008-09-27       Impact factor: 3.168

7.  Analysis of avian leukosis virus DNA and RNA in bursal tumours: viral gene expression is not required for maintenance of the tumor state.

Authors:  G S Payne; S A Courtneidge; L B Crittenden; A M Fadly; J M Bishop; H E Varmus
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

8.  Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.

Authors:  Sanggu Kim; Namshin Kim; Beihua Dong; David Boren; Serena A Lee; Jaydip Das Gupta; Christina Gaughan; Eric A Klein; Christopher Lee; Robert H Silverman; Samson A Chow
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

9.  Mutational analysis of the N-terminal domain of Moloney murine leukemia virus capsid protein.

Authors:  Marcy R Auerbach; Kristy R Brown; Ila R Singh
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

10.  Sexual behaviour, STDs and risks for prostate cancer.

Authors:  R B Hayes; L M Pottern; H Strickler; C Rabkin; V Pope; G M Swanson; R S Greenberg; J B Schoenberg; J Liff; A G Schwartz; R N Hoover; J F Fraumeni
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  161 in total

1.  A cautionary tale of virus and disease.

Authors:  Robin A Weiss
Journal:  BMC Biol       Date:  2010-09-27       Impact factor: 7.431

2.  XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

Authors:  Jui Pandhare-Dash; Chinmay K Mantri; Yuanying Gong; Zhenbang Chen; Chandravanu Dash
Journal:  Prostate       Date:  2011-09-19       Impact factor: 4.104

3.  NF-kappaB activation stimulates transcription and replication of retrovirus XMRV in human B-lineage and prostate carcinoma cells.

Authors:  Shuhei Sakakibara; Kaori Sakakibara; Giovanna Tosato
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

4.  No evidence of xenotropic murine leukaemia virus-related virus in French blood donors.

Authors:  Mhammed Touinssi; Rathviro Uch; Jean-François Cantaloube; Philippe De Micco; Philippe Biagini
Journal:  Blood Transfus       Date:  2012-02-22       Impact factor: 3.443

Review 5.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

6.  Mouse retroviruses and chronic fatigue syndrome: Does X (or P) mark the spot?

Authors:  Valerie Courgnaud; Jean-Luc Battini; Marc Sitbon; Andrew L Mason
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-23       Impact factor: 11.205

7.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

8.  Absence of detectable xenotropic murine leukemia virus-related virus in plasma or peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected blood donors or individuals in Africa.

Authors:  Shixing Tang; Jiangqin Zhao; Ragupathy Viswanath; Phillipe N Nyambi; Andrew D Redd; Armeta Dastyar; Lisa A Spacek; Thomas C Quinn; Xue Wang; Owen Wood; Durga Gaddam; Krishnakumar Devadas; Indira K Hewlett
Journal:  Transfusion       Date:  2010-11-15       Impact factor: 3.157

9.  Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer.

Authors:  Faraz Ahmed Baig; Talat Mirza; Amna Hamid; Serajuddaula Syed; Qamar Jamal
Journal:  Turk J Urol       Date:  2017-07-31

10.  The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.

Authors:  Michael J Metzger; Christiana J Holguin; Ramon Mendoza; A Dusty Miller
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.